What is the most recent earnings date for ORMP stock?
ORAMED PHARMACEUTICALS INC (ORMP) last reported earnings on 3/26/2026.
ORAMED PHARMACEUTICALS INC (ORMP) Earnings History & Surprises
NASDAQ:ORMP • US68403P2039
Current stock price
3.42 USD
+0.03 (+0.88%)
Last:
ORMP Earnings overview
Past quarterly earnings results for ORAMED PHARMACEUTICALS INC (ORMP), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Aug 12, 2026
Last Reported
Most Recent- Release Date
- Mar 26, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.24
- EPS Surprise
- %
- Revenue Surprise
- %
Beat Rate
Last 8 Quarters 38%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.24 | 0.00 | - | - | - | - | ||
| Q3 2025 | 1.12 | -0.04 | 2,845.10% | 333.33% | - | - | ||
| Q2 2025 | 0.31 | -0.04 | 859.80% | 19.23% | - | - | ||
| Q1 2025 | -0.19 | -0.01 | -1,762.75% | -575.00% | 2M | - | - | |
| Q4 2024 | 0.00 | -0.03 | 100.00% | -100.00% | - | - | ||
| Q3 2024 | -0.48 | 0.01 | -9,511.76% | -500.00% | - | - | ||
| Q2 2024 | 0.26 | 0.01 | 2,449.02% | 966.67% | 255K | -100.00% | -100.00% | |
| Q1 2024 | 0.04 | 0.02 | 96.08% | 150.00% | 510K | -100.00% | -100.00% | |
| Q4 2023 | 0.33 | -0.12 | 369.61% | 250.00% | - | -100.00% | ||
| Q3 2023 | -0.08 | -0.09 | 7.73% | 55.56% | 714K | -100.00% | -100.00% | |
| Q2 2023 | -0.03 | -0.10 | 70.59% | 88.89% | 674K | 714K | -5.60% | 0.60% |
| Q1 2023 | -0.08 | -0.27 | 69.83% | 70.37% | 666K | 765K | -12.94% | -0.60% |
| Q4 2022 | -0.22 | -0.23 | 5.40% | -6.51% | 680K | 736.644K | -7.69% | 1.49% |
| Q3 2022 | -0.18 | -0.26 | 30.34% | -5.88% | 680K | 706.35K | -3.73% | - |
| Q2 2022 | -0.27 | -0.22 | -21.70% | -58.82% | 670K | 714K | -6.16% | -1.47% |
| Q1 2022 | -0.27 | -0.23 | -15.09% | -17.39% | 670K | 714K | -6.16% | - |
| Q4 2021 | -0.21 | -0.17 | -22.73% | -72.13% | 670K | 714K | -6.16% | - |
| Q3 2021 | -0.17 | -0.19 | 9.91% | -70.00% | 680K | 1.275M | -46.67% | - |
| Q2 2021 | -0.17 | -0.20 | 16.67% | 19.05% | 680K | 1.088M | -37.50% | - |
| Q1 2021 | -0.23 | -0.18 | -28.85% | -53.33% | 670K | 714K | -6.16% | - |
| Q4 2020 | -0.12 | -0.15 | 18.86% | - | 670K | 653.31K | 2.55% | - |
| Q3 2020 | -0.10 | -0.21 | 52.56% | - | 680K | 1.456M | -53.30% | - |
| Q2 2020 | -0.21 | -0.17 | -22.91% | - | 680K | 516.12K | 31.75% | - |
| Q1 2020 | -0.15 | -0.18 | 15.97% | - | 670K | 331.5K | 102.11% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
510.54%
Max EPS beat (4)
2,845.10%
Min EPS beat (4)
-1,762.75%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, ORMP has beaten EPS estimates in 3 out of 4 releases
In the last 4 quarters, ORMP has beaten the EPS estimates by 510.5% on average.
Related analysis
ORAMED PHARMACEUTICALS INC / ORMP Earnings FAQ
Did ORMP stock beat earnings estimates in the most recent quarter?
ORAMED PHARMACEUTICALS INC (ORMP) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often ORAMED PHARMACEUTICALS INC beats earnings estimates?
In the last 4 quarters, ORAMED PHARMACEUTICALS INC (ORMP) has beaten EPS estimates in 3 out of 4 releases.